ReviewRecent insights into platinum drug resistance in cancer
References (144)
- et al.
Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's anticancer drug screen panel
Biochem Pharmacol
(1996) - et al.
Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer
Annals Oncol
(1996) - et al.
Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines
Annals Oncol
(1996) - et al.
A trial of lobaplatin (D-19466) in platinum-resistant ovarian cancer
Gynecol. Oncol
(1995) - et al.
Synthesis, characterization, and antitumor activity of a series of novel cisplatin analogs with cis-1,4-diaminocyclohexane as nonleaving amine group
J Inorg Biochem
(1996) The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes
Pharmacol. Ther
(1987)- et al.
Resistance to alkylatin agents and cisplatin: insights from ovarian carcinoma model systems
Pharmacol Ther
(1990) - et al.
Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines
Biochem Pharmacol
(1994) - et al.
Restorative effects of calmodulin antagonists on reduced cisplatin uptake by cisplatin-resistant human ovarian carcinoma cells
Gynecol Oncol
(1990) - et al.
Do cMOAT (MRP2), other MRP homologues, and LRP play a role in MDR?
Semin. Cancer Biol
(1997)
An evaluation of the role of glutathione and its associated enzymes in the expression of differential sensitivities to antitumor agents shown by a range of human tumour cell lines
Biochem Pharmacol
(1990)
The relationship between nuclear glutathione levels and resistance to melphalan in human ovarian tumour cells
Biochem Pharmacol
(1991)
Augmentation of adriamycin, melphalan and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian cancer cell lines by buthionine sulfoximine mediated glutathione depletion
Biochem Pharmacol
(1985)
Characterization of the reactions of platinum antitumor agents with biologic and nonbiologic sulfur-containing nucleophiles
Biochem Pharmacol
(1987)
Glutathione-associated cisdiamminedichloroplatinum (II) metabolism and ATP-dependent efflux from leukemia cells
J Biol Chem
(1993)
Cross-linking of glutathione to DNA by cancer chemotherapeutic platinum coordination complexes
Chem Biol Interact
(1987)
Drug resistance to cisdiamminedichloroplatinum (II) in Chinese hamster ovary cell lines by transfection with glutathione S-transferase gene
Biochem Biophys Res Comm
(1990)
Glutathione S-transferase π as a determinant of drug resistance in transfectant cell lines
J Biol Chem
(1990)
The role of metallothionein, glutathione, glutathione S-transferases and DNA repair in resistance to platinum drugs in a series of L1210 cell lines made resistant to anticancer platinum agents
Biochem Pharmacol
(1993)
Properties of the reaction of cis-dichlorodiammineplatinum(II) with metallothionein
J Biol Chem
(1992)
Sensitisation of human ovarian carcinoma cells to cis-diamminedichloroplatinum (II) by amphotericin B in vitro and in vivo
Eur J Cancer
(1994)
DNA excision repair pathways
Curr Opin Genet & Dev
(1997)
Nucleotide Excision Repair in Mammalian Cells
J Biol Chem
(1997)
Analysis of Incision Sites Produced by Human Cell Extracts and Purified Proteins during Nucleotide Excision Repair of a 1,3-Intrastrand d(GpTpG)-Cisplatin Adduct
J Biol Chem
(1996)
Evidence that mammalian cells possess homologous recombinational repair pathways
Mutat Res
(1996)
Nucleotide excision repair and the link with transcription
Trends Biochem Sci
(1995)
Enhanced host cell reactivation capacity and expression of DNA repair genes in human breast cancer cells resistant to bi-functional alkylating agents
Mutat. Res
(1995)
Purification of Nuclear Proteins That Bind to Cisplatin-damaged DNA
J Biol Chem
(1992)
The HMG-domain protein Ixrl blocks excision repair of cisplatin-DNA adducts in yeast
Mutat Res
(1996)
Cisplatin and its analogues
The mechanism of action of antitumor platinum compounds Prog
Nucleic Acids Res
(1979)
A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support
J Clin Oncol
(1989)
Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer
J Clin Oncol
(1992)
Phase I and pharmacokinetic study of ormaplatin (tetraplatin, NSC 363812) administered on a day 1 and day 8 schedule
Cancer Res
(1994)
Preclinical activity of a new platinum analogue, lobaplatin, in cisplatin-sensitive and -resistant human testicular, ovarian, and gastric carcinoma cell lines
Cancer Chemother. Pharmacol
(1993)
Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer
Br J Cancer
(1995)
A clinical screening cooperative group phase II evaluation of lobaplatin (ASTA D-19466) in advanced head and neck cancer
Invest New Drugs
(1995)
Chemical and biological studies on a series of novel (trans-(1R,2R)-, trans-(1S,2S)-, and cis-1,2-diaminocyclohexane)platinum (IV) carboxylate complexes
J. Med Chem
(1997)
Initiatives with platinum- and quinazoline-based antitumor molecules — Fourteenth Bruce F. Cain memorial award lecture
Cancer Res
(1995)
In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473
Br J Cancer
(1998)
Structurally novel platinum antitumor compounds
DNA interactions of bifunctional dinuclear platinum (II) antitumor agents
Eur J Biochem
(1997)
The quantitative detection of various Pt-DNA-adducts in Chinese hamster ovary cells treated with cisplatin: application of immunochemical techniques
Carcinogenesis
(1985)
Adducts of the antitumor drug cis-diamminedichloroplatinum (II) with DNA: formation, identification and quantitation
Biochemistry
(1985)
Formation of DNA adducts by the anticancer drug carboplatin: different nucleotide sequence preferences in vitro and in cells
Biochemistry
(1995)
Structural aspects of platinum anticancer drug interactions with DNA
Chem Rev
(1987)
An intrastrand d(GpG) platinum crosslink in duplex M13 DNA is refractory to repair by human cell extracts
Mechanism of cytotoxicity of anticancer platinum drugs: evidence that cisdiamminedichloroplatinum(II) and cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) differ only in the kinetics of their interaction with DNA
Cancer Res
(1986)
In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured cells
Carcinogenesis
(1996)
Mechanisms of resistance to cisplatin
Cancer Treat Res
(1991)
Cited by (0)
Copyright © 1998 Published by Elsevier Ltd.